KPTI
Karyopharm Therapeutics Inc.·Healthcare
8.00
1.961%(−0.16)
Market ClosedLast Updated: — ET
52W L: $3.6552W H: $10.99
KPTI NEWS
defenseworld.net
Apr 3
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy
defenseworld.net
Apr 2
Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 20.9%
Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 3,592,118 shares, an increase of 20.9% from the February 26th total of 2,971,195 shares. Approximately 19.9% of the company's shares are short sold.
zacks.com
Mar 27
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
seekingalpha.com
Mar 26
Karyopharm: Putting The Phase 3 Trial In Context
Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement, while showing a promising, though immature, overall survival signal. Dire cash position persists despite a $30 million private placement; runway extends only into Q2 2026, with existential funding risks looming.
zacks.com
Mar 25
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
seekingalpha.com
Mar 24
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript
